Cited by 1,422Acute Lymphoblastic Leukemia researchLymphoma Diagnosis and TreatmentGenomic variations and chromosomal abnormalities

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia

Open access

Mullighan, Charles G., Su, Xiaoping, Zhang, Jinghui, Radtke, Ina, Phillips, Letha A.A., Miller, Christopher B., Ma, Jing, Liu, Wei, Cheng, Cheng, Schulman, Brenda A., Harvey, Richard C., Chen, I-Ming, Clifford, Robert J., Carroll, William L., Reaman, Gregory, Bowman, W. Paul, Devidas, Meenakshi, Gerhard, Daniela S., Yang, Wenjian, Relling, Mary V., Shurtleff, Sheila A., Campana, Dario, Borowitz, Michael J., Pui, Ching-Hon, Smith, Malcolm, Hunger, Stephen P., Willman, Cheryl L., Downing, James R.·2009·New England Journal of Medicine

DOI 10.1056/nejmoa0808253PMC PMC2674612

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Despite best current therapy, up to 20% of pediatric patients with acute lymphoblastic leukemia (ALL) have a relapse. Recent genomewide analyses have identified a high frequency of DNA copy-number abnormalities in ALL, but the prognostic implications of these abnormalities have not been defined. METHODS: We studied a cohort of 221 children with high-risk B-cell-progenitor ALL with the use of single-nucleotide-polymorphism microarrays, transcriptional profiling, and resequencing of samples obtained at diagnosis. Children with known very-high-risk ALL subtypes (i.e., BCR-ABL1-positive ALL, hypodiploid ALL, and ALL in infants) were excluded from this cohort. A copy-number abnormality was identified as a predictor of poor outcome, and it was then tested in an independent validation cohort of 258 patients with B-cell-progenitor ALL. RESULTS: More than 50 recurring copy-number abnormalities were identified, most commonly involving genes that encode regulators of B-cell development (in 66.8% of patients in the original cohort); PAX5 was involved in 31.7% and IKZF1 in 28.6% of patients. Using copy-number abnormalities, we identified a predictor of poor outcome that was validated in the independent validation cohort. This predictor was strongly associated with alteration of IKZF1, a gene that encodes the lymphoid transcription factor IKAROS. The gene-expression signature of the group of patients with a poor outcome revealed increased expression of hematopoietic stem-cell genes and reduced expression of B-cell-lineage genes, and it was similar to the signature of BCR-ABL1-positive ALL, another high-risk subtype of ALL with a high frequency of IKZF1 deletion. CONCLUSIONS: Genetic alteration of IKZF1 is associated with a very poor outcome in B-cell-progenitor ALL.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa0808253

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan‐Smith, E., Dalton, J., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,777
Self-citation
Acute lymphoblastic leukaemia
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Self-citation
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Mullighan, C. G., Miller, C. B., Radtke, I., Phillips, L. A., Dalton, J., Ma, J., White, D., Hughes, T. P., Le Beau, M. M., Pui, C.-H., et al. (2008) · Nature · doi:10.1038/nature06866 · Cited by 1,072
Self-citation
The ikaros gene is required for the development of all lymphoid lineages
Georgopoulos, K., Bigby, M., Wang, J.-H., Molnar, A., Wu, P., Winandy, S., & Sharpe, A. (1994) · Cell · doi:10.1016/0092-8674(94)90407-3 · Cited by 985
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
Borowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S. B., Martin, P. L., Pullen, D. J., Viswanatha, D. S., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 841
Self-citation
Prediction by Supervised Principal Components
Bair, E., Hastie, T. J., Paul, D., & Tibshirani, R. J. (2006) · Journal of the American Statistical Association · doi:10.1198/016214505000000628 · Cited by 824
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Mullighan, C. G., Phillips, L. A., Su, X., Ma, J., Miller, C. B., Shurtleff, S. A., & Downing, J. R. (2008) · Science · doi:10.1126/science.1164266 · Cited by 806
Self-citation
On testing the significance of sets of genes
Efron, B., & Tibshirani, R. J. (2007) · The Annals of Applied Statistics · doi:10.1214/07-aoas101 · Cited by 785
Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data
Bair, E., & Tibshirani, R. J. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020108 · Cited by 749

Flagged first, then by citations

Show all 37 references

Research works printed but not linked: 3

Shuster JJ, 1999, Cancer Res Ther Control, 9, 101
Pui CH, 2006, Ann Hematol, 85, 88
Mirebeau D, 2006, Haematologica, 91, 881

Sorted by citations

Items 801–900 of 1,000

Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies
Hayette, S., Grange, B., Vallée, M., Bardel, C., Huet, S., Mosnier, I., Chabane, K., Simonet, T., Balsat, M., Heiblig, M., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000522 · Cited by 11
Impact of IKZF1 Deletions in the Prognosis of Childhood Acute Lymphoblastic Leukemia in Argentina
Felice, M. S., Rubio, P. L., Digiorge, J. A., Frank, M. B., Martínez, C. S., Guitter, M. R., Sajaroff, E. O., Rosa, C. G. S. L., Pennella, C. L., Peruzzo, L. B., et al. (2022) · Cancers · doi:10.3390/cancers14133283 · Cited by 10
Ikaros Regulates microRNA Networks in Acute Lymphoblastic Leukemia
Kogut, S., Paculová, H., Rodriguez, P. D., Boyd, J. R., Richman, A. R., Palaria, A., Schjerven, H., & Frietze, S. E. (2022) · Epigenomes · doi:10.3390/epigenomes6040037 · Cited by 11
PAX5-KIAA1549L: a novel fusion gene in a case of pediatric B-cell precursor acute lymphoblastic leukemia
Anderl, S., König, M., Attarbaschi, A., & Strehl, S. (2015) · Molecular Cytogenetics · doi:10.1186/s13039-015-0138-3 · Cited by 10
Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia
Iacobucci, I., Lonetti, A., Papayannidis, C., & Martinelli, G. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990089 · Cited by 10
Treatment outcome of young children with acute lymphoblastic leukaemia: achievements and directions implied from Shanghai Children's Medical Centre based SCMC ‐ ALL ‐2005 protocol
Liang, Y., Yang, L., Jiang, H., Yuan, X., Sun, L., Wang, N., & Tang, J. (2015) · British Journal of Haematology · doi:10.1111/bjh.13288 · Cited by 10
NK-Cell and B-Cell Deficiency with a Thymic Mass
Ng, S. Y., Fanta, C. H., Okam, M. M., & Bhatt, A. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1012485 · Cited by 10
Advances in B-lymphoblastic leukemia: cytogenetic and genomic lesions
Zhou, Y., Kanagal‐Shamanna, R., Zuo, Z., Tang, G., Medeiros, L. J., & Bueso-Ramos, C. (2016) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2016.02.002 · Cited by 10
Molecular/Cytogenetic Education for Hematopathology Fellows
Beck, R. C., Kim, A. S., Goswami, R. S., Weinberg, O. K., Yeung, C. C. S., & Ewalt, M. D. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa038 · Cited by 10
The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL
Bornhauser, B. C., Cario, G., Rinaldi, A. M., Risch, T., Martinez, V. R., Schütte, M., Warnatz, H.-J., Scheidegger, N. K., Mirkowska, P., Temperli, M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000938 · Cited by 10
IKZF1 Deletion Subtyping and Outcome Analysis in BCR–ABL1-Negative Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Institution Experience from North India
Gupta, S., Bakhshi, S., Gupta, R., Sharma, P., Pushpam, D., Sahoo, R. K., & Kamal, V. K. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.03.007 · Cited by 10
N‐terminus DUX4 ‐immunohistochemistry is a reliable methodology for the diagnosis of DUX4‐fused B‐lymphoblastic leukemia/lymphoma (N‐terminus DUX4 IHC for DUX4 ‐fused B‐ALL )
Siegele, B. J., Stemmer-Rachamimov, A. O., Lilljebjörn, H., Fioretos, T., Winters, A. C., Cin, P. D., Treece, A. L., Gaskell, A., & Nardi, V. (2022) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23033 · Cited by 10
Surrogate marker profiles for genetic lesions in acute leukemias
Paietta, E. M. (2010) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2010.08.001 · Cited by 10
CD25 Expression in B Lymphoblastic Leukemia/Lymphoma Predicts t(9;22)(q34;q11)/Philadelphia Chromosome Translocation (Ph) and Is Associated With Residual Disease in Ph-Negative Patients
Chen, P., Chu, A., Zia, H. M., Koduru, P. R. K., Collins, R. J., Winick, N. J., Fuda, F. S., & Chen, W. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw178 · Cited by 10
How should we treat the AYA patient with newly diagnosed ALL?
Boissel, N. (2017) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2017.07.008 · Cited by 10
Acute lymphoblastic leukemia: a genomic perspective
Jiménez‐Morales, S., Hidalgo‐Miranda, A., & Ramírez‐Bello, J. (2017) · Boletín Médico Del Hospital Infantil de México (English Edition) · doi:10.1016/j.bmhime.2017.11.013 · Cited by 10
Expression of Ik6 and Ik8 Isoforms and Their Association with Relapse and Death in Mexican Children with Acute Lymphoblastic Leukemia
Reyes-León, A., Juárez-Velázquez, R., Medrano-Hernández, A., Cuenca-Roldán, T., Salas‐Labadía, C., Navarrete-Meneses, M. D. P., Rivera‐Luna, R., López‐Hernández, G., Paredes-Aguilera, R. A., & Pérez‐Vera, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130756 · Cited by 10
Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia
Alsagaby, S. A. (2019) · Oncology Reviews · doi:10.4081/oncol.2019.435 · Cited by 10
Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis
Kovach, A. E., & Wood, B. L. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.10.001 · Cited by 9
Concepts in B cell acute lymphoblastic leukemia pathogenesis
Garcia, C., Miller, M. D., & Witkowski, M. T. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae015 · Cited by 9
A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission
Rahman, Z. A., Othman, T. A., Saliba, R. M., Vanegas, Y. A. M., Mohty, R., Ledesma, C., Rondón, G., Jain, N., Jabbour, E. J., Pullarkat, V. A., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.09.020 · Cited by 9
A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia
Goulart, H. E., Jabbour, E. J., Short, N. J., Kadia, T. M., Pemmaraju, N., Takahashi, K., Ravandi, F., Konopleva, M. Y., & Jain, N. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.05.013 · Cited by 9
Complementary regulation of early B-lymphoid differentiation by genetic and epigenetic mechanisms
Yokota, T., Sudo, T., Ishibashi, T., Doi, Y., Ichii, M., Orirani, K., & Kanakura, Y. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1424-7 · Cited by 9
Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia
Ceppi, F., Rizzati, F., Colombini, A., Conter, V., & Cazzaniga, G. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1967137 · Cited by 9
Novel gene signature reveals prognostic model in acute lymphoblastic leukemia
Chen, P., Gao, G., Xu, Y., Jia, P., Li, Y., Li, Y., Cao, J., Du, J., Zhang, S., & Zhang, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1036312 · Cited by 9
Self-citation
Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL
Tian, Z., Shi, C., Yang, G., Allen, J. K., Shi, Q., Al-Shami, A., Olson, J. W., Smith, M. G., Chang, Q., Kaur, J., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02010-y · Cited by 9
Self-citation
Genetics of Acute Lymphoblastic Leukemia
Maribel, R., Hernndez, M., & Mara, J. (2013) · InTech eBooks · doi:10.5772/55504 · Cited by 9
Evaluation of chronic lymphocytic leukemia by BAC-based microarray analysis
Schultz, R. A., Delioukina, M. L., Gaal, K. K., Bedell, V., Smith, D. D., Forman, S. J., McDaniel, L. D., Ballif, B. C., Shaffer, L. G., & Slovak, M. L. (2011) · Molecular Cytogenetics · doi:10.1186/1755-8166-4-4 · Cited by 9
AACR precision medicine series: Highlights of the integrating clinical genomics and cancer therapy meeting
Maggi, E. C., & Montagna, C. (2015) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2015.10.005 · Cited by 9
Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB
Solomon, L. A., Batista, C. R., & DeKoter, R. P. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.09.002 · Cited by 9
Clinical utility of targeted NGS panel with comprehensive bioinformatics analysis for patients with acute lymphoblastic leukemia
Kim, B., Lee, H., Kim, E., Shin, S., Lee, S., & Choi, J. R. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1627538 · Cited by 9
Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study
Norvilas, R., Dirsė, V., Semaškevičienė, R., Mickevičiūtė, O., Gineikienė, E., Stoškus, M., Vaitkevičienė, G. E., Rascon, J., & Griškevičius, L. (2021) · BMC Cancer · doi:10.1186/s12885-020-07781-6 · Cited by 9
Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation
Wang, L., Howarth, A., & Clark, R. E. (2014) · Leukemia · doi:10.1038/leu.2014.99 · Cited by 9
Novel methods and approaches to acute lymphoblastic leukemia drug discovery
Wei, M. C., & Cleary, M. L. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.956720 · Cited by 9
Mouse Lymphoblastic Leukemias Induced by Aberrant Prdm14 Expression Demonstrate Widespread Copy Number Alterations Also Found in Human ALL
Simko, S. J., Voicu, H., Carofino, B. L., & Justice, M. J. (2012) · Cancers · doi:10.3390/cancers4041050 · Cited by 9
Notch Target Gene Deregulation and Maintenance of the Leukemogenic Phenotype Do Not Require RBP-Jκ in Ikaros Null Mice
Chari, S., Umetsu, S. E., & Winandy, S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903688 · Cited by 9
Identification of prognostic risk factors of acute lymphoblastic leukemia based on mRNA expression profiling
Li, C., Kuang, L., Zhu, B., Chen, J., Wang, X., & Huang, X. (2017) · Neoplasma · doi:10.4149/neo_2017_402 · Cited by 9
Leukaemic alterations of IKZF1 prime stemness and malignancy programs in human lymphocytes
Li, Z., Shuiping, L., Li, R., Zhu, H., Liu, X., Guo, X., Mu, L., Cai, J.-J., Bai, F., Chen, G., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0600-3 · Cited by 9
ShinyCNV: a Shiny/R application to view and annotate DNA copy number variations
Gu, Z., & Mullighan, C. G. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty546 · Cited by 9
Self-citation
Feedforward regulation of Myc coordinates lineage-specific with housekeeping gene expression during B cell progenitor cell differentiation
Ferreirós-Vidal, I., Carroll, T., Zhang, T., Lagani, V., Ramírez, R. N., Ing‐Simmons, E., Gómez-Valadés, A. G., Cooper, L., Liang, Z., Παπουτσόγλου, Γ., et al. (2019) · PLoS Biology · doi:10.1371/journal.pbio.2006506 · Cited by 9
Can Ph-like ALL be effectively targeted?
Maese, L. D., & Raetz, E. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.101096 · Cited by 9
Integrated Genomic Analysis of Chromosomal Alterations and Mutations in B-Cell Acute Lymphoblastic Leukemia Reveals Distinct Genetic Profiles at Relapse
Forero‐Castro, M., Montaño, A., Robledo, C., de Coca, A. G., Fuster, J. L., Heras, N. D. L., Queizán, J. A., Hernández‐Sánchez, M., Corchete, L. A., Martín‐Izquierdo, M., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10070455 · Cited by 9
Aktuelle Therapie der akuten lymphatischen Leukämie des Erwachsenen
Gökbuget, N. (2015) · Der Internist · doi:10.1007/s00108-014-3595-6 · Cited by 11
Attacking Remaining Challenges in Childhood Leukemia
Rabin, K. R. (2012) · New England Journal of Medicine · doi:10.1056/nejme1200989 · Cited by 9
The IKAROS Transcription Factor Gene IKZF1 as a Critical Regulator in the Pathogenesis of Childhood Acute Lymphoblastic Leukemia: Insights from a Bangladeshi Population
Nila, N. N., Tamanna, S., Mahmud, Z., Washif, M., Ahmad, T., Rahman, A., & Howlader, M. Z. H. (2024) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-024-01218-8 · Cited by 8
SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia
Iacobucci, I., & Papayannidis, C. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.08.005 · Cited by 8
The CD123 antibody–drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia
Watts, B., Smith, C. M., Evans, K. L., Gifford, A. J., Mohamed, S. M. A., Erickson, S. W., Earley, E. J., Neuhauser, S. B., Stearns, T. M., Philip, V. M., et al. (2025) · HemaSphere · doi:10.1002/hem3.70063 · Cited by 8
Self-citation
Integrating Blinatumomab in the Frontline Treatment in B-Cell Acute Lymphoblastic Leukemia: A New Era in Therapeutic Management
Canichella, M., Fazio, L. D., & Molica, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062055 · Cited by 9
Prognostic significance of IKZF1 alteration status in pediatric B-lineage acute lymphoblastic leukemia: a meta-analysis
Feng, J., & Tang, Y. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.723212 · Cited by 8
Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes
Khazal, S. J., & Kebriaei, P. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1933475 · Cited by 8
Prognostic significance of copy number variation in B-cell acute lymphoblastic leukemia
Song, Y., Fang, Q., & Mi, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.981036 · Cited by 8
Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series
Hu, M., Liu, R., Li, J., Zhang, L., Cao, J., Yue, M., Zhong, D., & Tang, R. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05245-y · Cited by 8
Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity
Liu, H., Huang, Y., Jaing, T., Wu, K., Chen, S., Wang, S., Yeh, T., Hsiao, C., Chang, T., Yen, H., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19338 · Cited by 8
Self-citation
Machine learning analysis of gene expression reveals TP53 Mutant-like AML with wild type TP53 and poor prognosis
Lee, Y., Baughn, L. B., Myers, C. L., & Sachs, Z. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01061-3 · Cited by 8
IKZF1 in acute lymphoblastic leukemia: the rise before the fall?
Østergaard, A., Boer, J. M., van Leeuwen, F. N., Pieters, R., & den Boer, M. L. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2396046 · Cited by 8
The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7–9, 2011
Hunger, S. P., Baruchel, A., Biondi, A., Evans, W. E., Jeha, S., Loh, M. L., Moericke, A., Pieters, R., Relling, M. V., Schmiegelow, K., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24354 · Cited by 8
Self-citation
The p16INK4A/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome
Chien, W. W., Catallo, R., Chebel, A., Baranger, L., Thomas, X., Béné, M. C., Gerland, L. M., Schmidt, A., Beldjord, K., Klein, N., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.01.008 · Cited by 8
Genomic evaluations of childhood acute lymphoblastic leukemia susceptibility across race/ethnicities.
Urayama, K. Y., & Manabe, A. (2014) · PubMed · Cited by 8
Constitutive Function of the Ikaros Transcription Factor in Primary Leukemia Cells from Pediatric Newly Diagnosed High-Risk and Relapsed B-precursor ALL Patients
Uckun, F. M., Ma, H., Ishkhanian, R., Arellano, M. L., Shahidzadeh, A., Termuhlen, A. M., Gaynon, P. S., & Qazi, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080732 · Cited by 8
Where can biology of childhood ALL be attacked by new compounds?
Bourquin, J., & Izraeli, S. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.005 · Cited by 8
Epidemiology and Etiology of Childhood ALL
Tulstrup, M., Stoltze, U. K., Schmiegelow, K., & Yang, J. J. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-39708-5_1 · Cited by 8
Upfront Treatment Influences the Composition of Genetic Alterations in Relapsed Pediatric B‐Cell Precursor Acute Lymphoblastic Leukemia
Yu, J., Waanders, E., van Reijmersdal, S. V., Antić, Ž., van Bosbeek, C. M., Sonneveld, E., de Groot, H., Fiocco, M. F., van Kessel, A. G., van Leeuwen, F. N., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000318 · Cited by 8
Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion
Oya, S., Morishige, S., Ozawa, H., Sasaki, K., Semba, Y., Yamasaki, Y., Nakamura, T., Aoyama, K., Seki, R., Mouri, F., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-03006-5 · Cited by 8
RAS pathway mutation is an added‐value biomarker in pediatric Philadelphia‐negative B‐cell acute lymphoblastic leukemia with IKZF1 deletions
Huang, Y., Liu, H., Jaing, T., Wu, K., Wang, S., Yen, H., Hsiao, C., Chen, S., Lin, P., Yeh, T., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28899 · Cited by 8
Aberrant GATA2 Activation in Pediatric B-Cell Acute Lymphoblastic Leukemia
Wang, H., Cui, B., Sun, H., Zhang, F., Rao, J., Wang, R., Zhao, S., Shen, S., & Liu, Y. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2021.795529 · Cited by 8
Acute Lymphoblastic Leukemia
Tomizawa, D., & Kiyokawa, N. (2017) · Springer eBooks · doi:10.1007/978-981-10-3886-0_2 · Cited by 8
JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN)
Glück, M., Dally, L., Jücker, M., & Ehm, P. A. H. (2022) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2022.106229 · Cited by 8
Layered immunity and layered leukemogenicity: Developmentally restricted mechanisms of pediatric leukemia initiation
Mendoza‐Castrejon, J., & Magee, J. A. (2023) · Immunological Reviews · doi:10.1111/imr.13180 · Cited by 9
Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid Tumors
Tsai, H. K., Gogakos, T., Lip, V., Tsai, J. M., Li, Y.-D., Fisch, A. S., Weiss, J., Yang, W., Grimmett, L., Ditoro, D. F., et al. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.06.007 · Cited by 8
Self-citation
Key pathways as therapeutic targets
Harrison, C. J. (2011) · Blood · doi:10.1182/blood-2011-07-362723 · Cited by 8
Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma
Waibel, M., Gregory, G. P., Shortt, J., & Johnstone, R. W. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000045 · Cited by 8
Ik6 expression provides a new strategy for the therapy of acute lymphoblastic leukemia
Zhou, F., Xu, Y., Qiu, Y., Wu, X., Zhang, Z., & Jin, R. (2014) · Oncology Reports · doi:10.3892/or.2014.2969 · Cited by 8
Whole-Genome Single Nucleotide Polymorphism Array Analysis Is Complementary to Classical Cytogenetic Analysis in the Evaluation of Lymphoid Proliferations
Gibson, S. E., Luo, J., Sathanoori, M., Liao, J., Surti, U., & Swerdlow, S. H. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcprhght28duwla · Cited by 8
Epidemiology of Acute Childhood Leukemia
Ross, J. A., Johnson, K. J., Spector, L. G., & Kersey, J. H. (2010) · Pediatric oncology · doi:10.1007/978-3-642-13781-5_1 · Cited by 8
Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR–JAK2 fusion transcript
Duployez, N., Nibourel, O., Ducourneau, B., Grardel, N., Boyer, T., Bories, C., Darre, S., Coiteux, V., Berthon, C., Preudhomme, C., et al. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12752 · Cited by 8
Expression of Ikaros Isoform 6 in Chinese Children With Acute Lymphoblastic Leukemia
Zhou, F., Mei, H., Jin, R., Li, X., & Chen, X. (2011) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e318217f5f2 · Cited by 8
Case report: Exome sequencing identifies T-ALL with myeloid features as a IKZF1-struck early precursor T-cell malignancy
Hansen, M. H., Nederby, L., Kjeldsen, E., Petersen, M. A., Ommen, H. B., & Hokland, P. (2017) · Leukemia Research Reports · doi:10.1016/j.lrr.2017.11.002 · Cited by 8
ETV6–ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia
Uemura, S., Nishimura, N., Hasegawa, D., Shono, A., Sakaguchi, K., Matsumoto, H., Nakamachi, Y., Saegusa, J., Yokoi, T., Tahara, T., et al. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2371-5 · Cited by 8
Expression of aberrantly spliced oncogenic Ikaros isoforms coupled with clonal IKZF1 deletions and chimeric oncogenes in acute lymphoblastic leukemia
Vshyukova, V., Valochnik, A. V., & Meleshko, A. (2018) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2018.02.001 · Cited by 8
Using genomics to define pediatric blood cancers and inform practice
Rau, R. E., & Loh, M. L. (2018) · Hematology · doi:10.1182/asheducation-2018.1.286 · Cited by 8
Cuplike nuclear morphology is highly associated with IKZF1 deletion in pediatric precursor B-cell ALL
Li, W., Cooley, L. D., August, K. J., Richardson, A. I., Shao, L., Ahmed, A. A., Farooqi, M. S., & Zwick, D. L. (2019) · Blood · doi:10.1182/blood.2019000604 · Cited by 8
Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias
Huang, B. J., Wandler, A. M., Meyer, L. K., Dail, M., Daemen, A., Sampath, D., Li, Q., Wang, X., Wong, J. C. Y., Nakitandwe, J., et al. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008168 · Cited by 8
Self-citation
Intracranial Hemorrhage Following Oral Low-Dose Methotrexate After Multiple Toxicities Caused by High-Dose Methotrexate in Childhood Acute Lymphoblastic Leukemia
Xin, N., Zhou, F., Li, C., Yan, X., & Runming, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01072 · Cited by 8
Data-driven approaches to advance research and clinical care for pediatric cancer
Gout, A. M., Arunachalam, S., Finkelstein, D., & Zhang, J. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188571 · Cited by 9
Self-citation
Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies
Bacher, U., Kohlmann, A., & Haferlach, T. (2009) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/elp011 · Cited by 9
Precursor B- and T-Cell Neoplasms
Racke, F. K., & Borowitz, M. J. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7216-0040-6.00041-1 · Cited by 8
Self-citation
Deciphering IGH rearrangement complexity and detection strategies in acute lymphoblastic leukaemia
Thomson, A. J., Rehn, J. A., Yeung, D. T. O., Breen, J., & White, D. L. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00887-9 · Cited by 7
From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents
Tasian, S. K., Boer, J. M., & den Boer, M. L. (2025) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2025.100304 · Cited by 7
PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia
Bedics, G., Egyed, B., Kotmayer, L., Benard-Slagter, A., de Groot, K., Bekő, A., Hegyi, L. L., Bátai, B., Krizsán, S., Kriván, G., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02309-8 · Cited by 7
The advances of E2A-PBX1 fusion in B-cell acute lymphoblastic Leukaemia
Yang, M., Tang, Y., Zhu, P., Lu, H., Wan, X., Guo, Q., Xiao, L., Liu, C., Guo, L., Liu, W., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05595-7 · Cited by 7
Self-citation
An integrated classification of tumor suppressor IKZF1 inactivation and oncogenic activation in Philadelphia chromosome‐like acute lymphoblastic leukemia
Huang, Z., Zhang, L., Gong, X., Li, J., Deng, S., Cai, Z., Tang, B., Huang, K., Li, X., Zhao, W., et al. (2024) · HemaSphere · doi:10.1002/hem3.82 · Cited by 7
Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia
Campana, D., & Pui, C. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_19 · Cited by 7
Self-citation
“Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions”—Treatment of ALL
Chiaretti, S., Jabbour, E. J., & Hoelzer, D. F. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.03.014 · Cited by 7
Microdeletion of 7p12.1p13, including IKZF 1, causes intellectual impairment, overgrowth, and susceptibility to leukaemia
Järviaho, T., Zachariadis, V., Tesi, B., Chiang, S. C. C., Bryceson, Y. T., Möttönen, M. I., Niinimäki, R., Bang, B., Rahikkala, E., Taylan, F., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15494 · Cited by 7
Significance of genetic polymorphisms in hematological malignancies: implications of risk factors for prognosis and relapse
Asnafi, A. A., Farshchi, N., Khosravi, A., Ketabchi, N., Behzad, M. M., & Shahrabi, S. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0446-5 · Cited by 7
BCR‐ABL1‐like B‐lymphoblastic leukemia/lymphoma: Review of the entity and detection methodologies
Conant, J. L., & Czuchlewski, D. R. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13012 · Cited by 7
An updated account on molecular heterogeneity of acute leukemia.
Rahul, E., Goel, H., Chopra, A., Ranjan, A., Gupta, A., Meena, J. P., Bakhshi, S., Misra, A., Hussain, S., Viswanathan, G. K., et al. (2021) · PubMed Central · Cited by 7
A New Treatment Strategy for Early T‐Cell Precursor Acute Lymphoblastic Leukemia: A Case Report and Literature Review
Mao, J., Xue, L.-G., Wang, H., Zhu, Y., Wang, J., & Zhao, L. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s312494 · Cited by 7
Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy
Nardi, V., McAfee, S. L., Cin, P. D., Tsai, H. K., Amrein, P. C., Hobbs, G. S., Brunner, A. M., Narayan, R., Foster, J., Fathi, A. T., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab052 · Cited by 7
MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia
Kaumeyer, B. A., Fidai, S. S., SUKHANOVA, M. J., Yap, K. L., Segal, J. P., Raca, G., Stock, W., McNeer, J. L., Lager, A. M., & Gurbuxani, S. K. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2025797 · Cited by 7

Authors: Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., Harvey, R. C., Chen, I.-M., Clifford, R. J., Carroll, W. L., Reaman, G., Bowman, W. P., Devidas, M., Gerhard, D. S., Yang, W., Relling, M. V., Shurtleff, S. A., Campana, D., Borowitz, M. J., Pui, C.-H., Smith, M., Hunger, S. P., Willman, C. L., & Downing, J. R.
Affiliations: St. Jude Children's Research Hospital (US)
National Institutes of Health (US)
UNM Comprehensive Cancer Center (US)
New York University (US)
Children's National (US)
Cook Children's Medical Center (US)
University of Florida Health (US)
Children's Hospital Colorado (US)
ORCID: Mullighan, Charles G.
Su, Xiaoping
Zhang, Jinghui
Radtke, Ina
Ma, Jing
Liu, Wei
Cheng, Cheng
Schulman, Brenda A.
Harvey, Richard C.
Chen, I-Ming
Clifford, Robert J.
Carroll, William L.
Reaman, Gregory
Bowman, W. Paul
Devidas, Meenakshi
Yang, Wenjian
Relling, Mary V.
Campana, Dario
Pui, Ching-Hon
Smith, Malcolm
Hunger, Stephen P.
Willman, Cheryl L.
Downing, James R.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2009-01-29
Volume: 360
Issue: 5
Pages: 470-480
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa0808253
PMC: PMC2674612
OpenAlex: W2040329520
Cited by: 1,422
References: 37
Citations by year: 2026: 30 · 2025: 50 · 2024: 66 · 2023: 90 · 2022: 66 · 2021: 103 · 2020: 92 · 2019: 69 · 2018: 74 · 2017: 105 · 2016: 96 · 2015: 101 · 2014: 84 · 2013: 90 · 2012: 98
FWCI: 101.04
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: U.S. Public Health Service (N01C012400, 21765)
National Cancer Institute (CA 098543, R01CA086011, U10CA098413, U01CA157937, R01 CA86011, U10CA098543, U01CA114762, CA114762, P30CA021765)
National Institute of General Medical Sciences (U01 GM61393, U01GM061374, U01-GM-61374, U01GM061393)
Topics: Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
Keywords: IKZF1 deletion, acute lymphoblastic leukemia, pediatric leukemia, copy number abnormalities, prognosis, PAX5, Ikaros, B cell development, gene expression signatures, relapse
MeSH terms: B-Lymphocytes, Child, DNA Mutational Analysis, Genotype, Hematopoietic Stem Cells, Humans, Prognosis, Recurrence, Cohort Studies, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Trans-Activators, Gene Expression, Treatment Outcome, Gene Deletion, Drug Resistance, Neoplasm, Mutation, Missense, Gene Expression Profiling, Ikaros Transcription Factor, PAX5 Transcription Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks